Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Tema Fodje

General Family Medicine · U.S. Navy

View

Dr. Reid Blackwelder

General Family Medicine · ETSU

View

Dr. Gregory Sawin

General Family Medicine · Duke University

View

Dr. Wendy Barr

General Family Medicine · Yale College

View

Dr. Sophie Lin

General Family Medicine · Houston Methodist

View

Dr. Enitza George

General Family Medicine · BMS Family Health & Wellness Centers

View

Dr. Kisha Davis

General Family Medicine

View

Dr. Joshua Coren

General Family Medicine · Rowan-Virtua

View

Dr. Megan Mahoney

General Family Medicine · UCSF

View

Dr. Deepa Thakor

General Family Medicine · Stanford

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Severe Transaminitis Without Rhabdomyolysis: An Unusual Presentation of Daptomycin-Induced Liver Injury.

    Oct 13, 2026DOI: 10.14309/crj.0000000000002352Case ReportsACG

    Written by: Imran KhokharKhaled ElsokaryMuhammad Haris LatifNavanita BiswasAyesha Kang

    INTRODUCTION

    Drug-induced liver injury (DILI) represents a significant clinical challenge, with more than 1,000 medications implicated as potential hepatotoxins.1 The pathophysiology of DILI is complex and involves multiple mechanisms, including direct hepatocellular toxicity, mitochondrial dysfunction, oxidative stress, and immune-mediated injury.1 Idiosyncratic DILI is uncommon, occurring in only 1 in 1,000 to 1 in a million exposed individuals, and is typically neither dose-related nor duration-related.2 Antibiotics are among the most common causes of idiosyncratic DILI, with amoxicillin-clavulanate, isoniazid, and trimethoprim-sulfamethoxazole being the most frequently implicated agents.2Daptomycin, a cyclic lipopeptide antibiotic with bactericidal activity against Gram-positive organisms, is generally well-tolerated. In phase 3 clinical trials, abnormal liver function tests occurred in 3.0% of patients receiving daptomycin compared with 1.6% in comparator groups.3 However, severe daptomycin-induced hepatotoxicity remains exceedingly rare. A retrospective cohort analysis of 614 patients receiving daptomycin at a single academic medical center identified only 1 case of probable DILI, highlighting the rarity of this adverse effect.4The clinical presentation of daptomycin-induced liver injury varies considerably. While some cases present with concurrent rhabdomyolysis and elevated creatine kinase (CK) levels, others demonstrate isolated hepatotoxicity without muscle or renal involvement.1,5 Marked transaminase elevations reaching levels typically associated with acetaminophen toxicity or ischemic hepatitis are particularly uncommon with daptomycin. We present a case of severe isolated transaminitis following daptomycin initiation, emphasizing the need for vigilant hepatic monitoring in patients receiving this antibiotic.

    CASE REPORT

    A 43-year-old man with a history of intravenous drug use presented to the hospital following a mechanical fall that resulted in right shoulder injury. Blood cultures grew methicillin-resistant Staphylococcus aureus (MRSA), and imaging studies revealed right retrocaval abscesses and paravertebral abscesses extending along the lumbar and thoracic spine. The patient was initially treated with intravenous vancomycin for MRSA bacteremia. However, based on subtherapeutic vancomycin trough levels indicating rapid drug clearance, the antibiotic regimen was changed to intravenous daptomycin at a dose of 8 mg/kg once daily (hospital day 4). The patient received daptomycin for a total of 6 days before it was discontinued on hospital day 10 due to rising transaminase levels.
    On hospital admission, baseline liver function tests demonstrated aspartate aminotransferase (AST) of 13 U/L and alanine aminotransferase (ALT) of 18 U/L, both within normal limits. Two days after initiating daptomycin therapy, AST and ALT increased to 47 and 54 U/L, respectively. Liver function tests were monitored daily without medication changes. Over the subsequent days, transaminase levels rose dramatically, with AST and ALT reaching peak values of 1,965 and 2,253 U/L, respectively, on hospital day 10 (Table 1). Notably, serum creatinine, blood urea nitrogen, and total bilirubin remained within normal limits throughout this period. Gamma-glutamyl transferase was elevated at 253 U/L, while CK remained normal at 47 U/L, effectively excluding rhabdomyolysis.
    Temporal pattern of transaminase elevation following daptomycin initiation
    The table demonstrates a rapid rise in both AST and ALT beginning on day 6 (2 days after daptomycin initiation on hospital day 4), with peak values on day 10, followed by progressive normalization after daptomycin discontinuation on day 10. Reference ranges: AST 10–40 U/L; ALT 7–56 U/L.
    ALT, alanine transaminase; AST, aspartate aminotransferase.
    Daptomycin (8 mg/kg/d) was discontinued on hospital day 10 due to markedly elevated transaminases.
    A comprehensive evaluation for alternative causes of acute hepatitis was undertaken. Alcohol use was denied by the patient, and acetaminophen levels were undetectable. The patient remained hemodynamically stable throughout his hospitalization, with no documented episodes of hypotension or hemodynamic instability that could suggest ischemic hepatitis. Hepatitis A immunoglobulin G and hepatitis B core antibody immunoglobulin M were negative. Although hepatitis C antibody was positive, hepatitis C RNA nucleic acid amplification testing was negative, indicating no active viral replication. Additional viral serologies, including Epstein-Barr virus and cytomegalovirus IgM, were negative, further excluding superimposed viral hepatitis as a contributing etiology. Blood cultures obtained during daptomycin therapy demonstrated clearance of MRSA bacteremia, confirming microbiological response to treatment. Autoimmune markers, including antinuclear antibody, anti-mitochondrial antibody, anti-smooth muscle antibody, and liver-kidney microsomal antibody, were all negative. Alkaline phosphatase (ALP) remained within the normal range at 72 U/L (normal: 44–147 U/L), yielding an R ratio of 17.5 [(ALT/ULN)/(ALP/ULN) = (2,253/40)/(72/95)], consistent with a hepatocellular pattern of injury. International normalized ratio was 1.1, reflecting preserved hepatic synthetic function. Abdominal ultrasound revealed mild hepatomegaly without evidence of abscess formation. Abdominal duplex ultrasound excluded portal vein and hepatic vein thrombosis as potential etiologies. Liver function tests were monitored on a daily basis as part of the routine inpatient infectious disease monitoring protocol for patients on prolonged antibiotic therapy, which facilitated early recognition of the rising transaminase trend.
    After careful review of the patient's medication history and temporal relationship between daptomycin initiation and transaminase elevation, the decision was made to discontinue daptomycin on hospital day 10. Following drug discontinuation, liver function tests improved progressively, with near-normalization of AST by day 13 and complete normalization of both AST and ALT by day 23 (approximately 13 days after discontinuation). No specific hepatoprotective treatment was required. The patient was transitioned to intravenous ceftaroline and completed a 4 to 6-week course of antibiotic therapy for his MRSA infection without further hepatic abnormalities during hospitalization.6

    DISCUSSION

    This case represents a rare presentation of daptomycin-induced liver injury characterized by severe isolated transaminitis without concurrent rhabdomyolysis, renal dysfunction, or hyperbilirubinemia. The temporal relationship between daptomycin initiation and transaminase elevation, exclusion of alternative etiologies, and rapid improvement following drug discontinuation strongly support a causal relationship based on the Roussel Uclaf Causality Assessment Method criteria for DILI.6
    The magnitude of transaminase elevation in our patient is particularly noteworthy. Peak AST and ALT levels exceeding 1,900 U/L and 2,200 U/L, respectively, are typically associated with acetaminophen toxicity, ischemic hepatitis, or acute viral hepatitis rather than idiosyncratic drug reactions.2 The hepatocellular pattern of injury, defined by an R ratio greater than 5, was confirmed in our patient: with a peak ALT of 2,253 U/L (upper limit of normal [ULN] 56 U/L) and alkaline phosphatase (ALP) of 72 U/L (ULN 95 U/L), the R ratio was calculated as (2,253/56)/(72/95) = 53.0, far exceeding the threshold of 5 that defines hepatocellular injury. This confirms direct hepatocyte damage rather than a cholestatic pattern of injury.2 The mechanism of daptomycin-induced hepatotoxicity remains unclear but may involve direct cellular toxicity, mitochondrial dysfunction, or immune-mediated injury, as described for other antibiotic-related liver injuries.1
    The clinical presentation of daptomycin-induced liver injury varies considerably in published case reports. Abraham et al described a 35-year-old patient who developed hepatotoxicity with concurrent acute renal failure in the absence of rhabdomyolysis or CK abnormalities after 5 weeks of daptomycin therapy.5 Similarly, our patient demonstrated isolated hepatotoxicity without muscle or renal involvement. This contrasts with other reports describing daptomycin-induced rhabdomyolysis accompanied by liver injury, suggesting multiple potential mechanisms of hepatotoxicity.1 Bohm et al reported a case of daptomycin-induced liver injury with transaminitis and hyperbilirubinemia without concurrent multiorgan dysfunction or CK elevation, further supporting the heterogeneous presentation of this adverse effect.4
    The absence of rhabdomyolysis in our patient is clinically significant. Daptomycin is well-known to cause myopathy and rhabdomyolysis, with CK monitoring recommended weekly during therapy.3 Daptomycin-associated myopathy has been identified in 2%–14% of patients, with rhabdomyolysis occurring in approximately 0.8% of cases.7 The dissociation between severe hepatotoxicity and normal CK levels suggests that hepatic and muscular toxicity may occur through independent mechanisms. This finding has important clinical implications, as clinicians monitoring only CK levels may miss isolated hepatotoxicity.
    The rapid normalization of liver enzymes following daptomycin discontinuation without specific treatment supports the diagnosis of DILI. It suggests a favorable prognosis when the offending agent is promptly identified and withdrawn. This case underscores the importance of maintaining a high index of suspicion for daptomycin-induced hepatotoxicity, particularly in patients receiving prolonged therapy for serious infections.
    In conclusion, while daptomycin-induced liver injury is rare, clinicians should be aware of this potential adverse effect and routinely monitor liver function tests in addition to CK levels in all patients receiving daptomycin therapy, regardless of CK trends. Severe isolated transaminitis can occur without rhabdomyolysis or renal dysfunction, and prompt recognition with drug discontinuation typically results in complete and rapid resolution of hepatic abnormalities. We recommend baseline liver function test measurement before daptomycin initiation with periodic monitoring thereafter, particularly for patients receiving prolonged courses or who present with risk factors of hepatotoxicity.

    DISCLOSURES

    Author contributions: I. Khokhar: Conceptualization; case identification; clinical data acquisition; supervision; critical revision of the manuscript for important intellectual content; final approval of the version to be published; accountable for all aspects of the work. K. Elsokary, MD: Clinical data acquisition and interpretation; contribution to clinical content; critical revision of the manuscript; final approval of the version to be published; accountable for all aspects of the work. MH Latif: Literature review; data interpretation; manuscript drafting; figure and table preparation; manuscript editing; coordination of submission and correspondence; final approval of the version to be published; accountable for all aspects of the work. A. Kang: Contribution to clinical data interpretation and contextualization; critical revision of the manuscript; final approval of the version to be published; accountable for all aspects of the work. N. Biswas: Contribution to case data review and interpretation; critical revision of the manuscript; final approval of the version to be published; accountable for all aspects of the work. I. Khokhar is the article guarantor.
    Financial disclosure: None to report.
    Informed consent was obtained for this case report.
    AKDr. Anthony Kang

    Dr. Anthony Kang

    Family Medicine · General Family Medicine
    anthonyk